Is This the Company Gilead Sciences Should Fear Most? (Hint: It’s Not Merck or AbbVie) | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 20 February, 2016 by The TZ Newswire Staff

Is This the Company Gilead Sciences Should Fear Most? (Hint: It’s Not Merck or AbbVie)

A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.

See also
- Next Article Market Snapshot: Home Depot, Target to wrap up dismal earnings season
- Previous Article NewsWatch: This one-two-three punch could drop stocks 30% in 2016
Editorial Calender

February 2016

M T W T F S S

1 2 3 4 5 6 7

8 9 10 11 12 13 14

15 16 17 18 19 20 21

22 23 24 25 26 27 28

29

« Jan Mar »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar